How to Get Dayvigo (Lemborexant) in New Hampshire

What Is Dayvigo and Why Do Physicians Prescribe It?

Dayvigo is an FDA-approved treatment for insomnia disorder that works by blocking both orexin-1 and orexin-2 receptors, the brain signaling pathways that promote wakefulness. By blunting that wake signal at bedtime, lemborexant shortens the time it takes to fall asleep and reduces middle-of-the-night awakenings without the sedative-hypnotic mechanism shared by benzodiazepines and Z-drugs.

The FDA granted approval for lemborexant 5 mg and 10 mg in December 2019, based primarily on the SUNRISE-1 and SUNRISE-2 trial programs [1]. In SUNRISE-1 (N=291), lemborexant 10 mg reduced subjective sleep onset latency by a mean of 18.7 minutes versus 5.0 minutes for placebo at month one (P<0.001) [1]. A companion polysomnography sub-study confirmed that lemborexant 10 mg reduced latency to persistent sleep by 17.1 minutes versus placebo [1].

The American Academy of Sleep Medicine (AASM) clinical practice guideline on pharmacologic treatments for insomnia states: "We suggest the use of lemborexant for sleep onset and sleep maintenance insomnia in adults" [2]. That conditional recommendation is grounded in trial data showing improvements in both subjective and objective sleep parameters [2].

Because lemborexant carries a Schedule IV classification under the Controlled Substances Act, prescribing it in New Hampshire requires a licensed provider with DEA registration and a valid prescriber-patient relationship [3]. New Hampshire RSA 318-B governs controlled substance prescribing statewide, and the New Hampshire Board of Medicine has explicitly confirmed that telehealth encounters can satisfy the prescriber-patient relationship requirement when clinical standards are met [4].

How New Hampshire Telehealth Law Applies to Dayvigo

New Hampshire permits synchronous telehealth visits for Schedule IV prescribing. No in-person visit is required.

Under New Hampshire RSA 329:1-d, a provider may prescribe a controlled substance via telemedicine if the encounter meets the same standard of care as an in-person visit and the provider is licensed to practice in New Hampshire [4]. The DEA's telemedicine rules for Schedule IV substances, published in the Federal Register in 2023, align with this standard for audio-video encounters [3]. What this means practically: a New Hampshire patient can complete an intake questionnaire, join a live video call with a licensed NH provider, and receive a Dayvigo prescription electronically to a New Hampshire pharmacy the same day.

HealthRX connects New Hampshire patients with providers licensed in the state. The intake process collects sleep history, the Insomnia Severity Index (ISI) score, current medications, and any relevant medical history. Providers review this information before the video visit, which typically runs 15 to 20 minutes. A prescription is transmitted electronically to the patient's chosen pharmacy if clinically appropriate.

Providers may choose to start at lemborexant 5 mg before titrating to 10 mg based on response and tolerability [5]. The FDA prescribing information notes that 10 mg is the maximum recommended dose and that the drug should not be taken if the patient cannot dedicate at least 7 hours to sleep [5]. Concomitant use with other CNS depressants warrants a dose reduction to 5 mg [5].

What Labs or Tests Are Needed Before Starting Lemborexant in New Hampshire?

No mandatory baseline labs are required before starting lemborexant.

Unlike thyroid replacement or testosterone therapy, lemborexant does not require a specific blood panel before the first prescription. The FDA label does not list pre-treatment laboratory requirements [5]. Providers typically review a standard medical history to rule out conditions that could mimic or worsen insomnia, including untreated sleep apnea, depression, and thyroid dysfunction. If a patient has not had a recent thyroid panel or mood screen, the prescriber may recommend those as adjunct evaluations, but they are not a gate to receiving the prescription.

A validated subjective tool, the Pittsburgh Sleep Quality Index (PSQI), and the Insomnia Severity Index are commonly used during the intake visit to establish baseline severity and track improvement over time [6]. The PSQI global score above 5 indicates poor sleep quality and is a useful documentation anchor for insurers when prior authorization is required [6]. Polysomnography is not required for a clinical insomnia diagnosis and is generally reserved for cases where sleep-disordered breathing is suspected [7].

Patients with moderate-to-severe hepatic impairment should not take lemborexant, and patients with mild hepatic impairment should start at 5 mg [5]. Providers in New Hampshire may order a liver function panel if clinical history warrants it, particularly in patients with alcohol use disorder or known liver disease.

Dayvigo Prior Authorization in New Hampshire: What Insurance Requires

Most commercial New Hampshire insurers require prior authorization for Dayvigo. Getting it approved typically takes 3 to 10 business days.

New Hampshire Medicaid does not cover Dayvigo as of 2025. For patients with commercial insurance, Cigna, Aetna, Anthem, and Harvard Pilgrim Health Care plans in New Hampshire generally place lemborexant on Tier 3 or Tier 4 of the formulary and require PA before dispensing [8]. The standard PA packet for insomnia medications in New Hampshire includes:

• A confirmed DSM-5 diagnosis of insomnia disorder (ICD-10 code G47.00 or G47.09)
• Documentation that a behavioral intervention such as Cognitive Behavioral Therapy for Insomnia (CBT-I) has been attempted or is contraindicated
• Evidence of prior trial and failure or intolerance of at least one preferred formulary agent, commonly zolpidem or eszopiclone
• The prescribing provider's DEA number and NH license number

The American College of Sleep Medicine has noted that CBT-I is the first-line treatment for chronic insomnia, and insurers use its absence as a PA denial trigger [2]. Patients who have genuinely attempted CBT-I, even through a digital platform like Sleepio, should document session dates in the PA request.

HealthRX providers in New Hampshire use a standardized PA documentation protocol that captures the ISI score, prior drug trials with dates and reasons for discontinuation, and the prescriber's clinical rationale for selecting lemborexant specifically. This framework reduces the back-and-forth that delays approval under most NH commercial plans.

For patients without insurance or whose PA is denied, lemborexant 10 mg has a GoodRx cash price in New Hampshire ranging from approximately $290 to $340 for a 30-tablet supply. Eisai's patient assistance program, Dayvigo Together, offers co-pay cards that may reduce out-of-pocket cost to as low as $15 for eligible commercially insured patients [9].

Finding a Dayvigo Pharmacy in New Hampshire

Any DEA-registered retail pharmacy in New Hampshire can fill a Dayvigo prescription.

Major chains with locations across New Hampshire, including CVS, Walgreens, Walmart Pharmacy, and Hannaford Pharmacy, all stock lemborexant in both 5 mg and 10 mg strengths. Because it is a Schedule IV controlled substance, the prescription must be transmitted electronically under New Hampshire RSA 318-B:21, with narrow exceptions for paper prescriptions in emergencies [4]. Mail-order fills are permitted; 90-day supplies require a new prescription each time under federal Schedule IV rules [3].

503A compounding pharmacies licensed by the New Hampshire Board of Pharmacy may compound lemborexant for patient-specific prescriptions when a commercially manufactured product is unavailable or a patient has a documented need for a different formulation [10]. As of 2025, the FDA has not placed lemborexant on the 503B bulk substances list, meaning large-scale outsourcing-facility compounding is not permitted [10]. Any NH 503A pharmacy filling a compounded lemborexant preparation must do so pursuant to a valid, patient-specific prescription from a licensed NH provider [10].

Patients who establish care through HealthRX in New Hampshire can have their prescription sent electronically to any in-state pharmacy of their choice, or to a mail-order partner with licensed NH pharmacist oversight.

How Long Does It Take to Receive Dayvigo in New Hampshire?

For telehealth patients in New Hampshire, the typical time from initial visit to first dose is 3 to 7 days.

The timeline breaks down as follows. The HealthRX intake form takes 10 to 15 minutes to complete. Scheduling a same-day or next-day video visit is usually possible during weekday business hours. If the provider prescribes lemborexant at the visit, the electronic prescription reaches the pharmacy within minutes. Local retail pharmacy filling takes 30 minutes to 2 hours for cash-pay patients. Insurance PA, when required, adds 3 to 10 business days.

Patients transferring an existing Dayvigo prescription from another state can ask their current pharmacy to transfer the remaining fills. Schedule IV prescriptions may be transferred between DEA-registered pharmacies, but only once under federal law [3]. Patients moving to New Hampshire who have exhausted transfers should schedule a new NH provider visit rather than relying on an out-of-state prescription.

Clinical Evidence Supporting Lemborexant Use

Lemborexant's efficacy rests on two Phase 3 randomized controlled trials, a long-term safety extension, and a head-to-head comparison.

SUNRISE-1 (N=291) was a 1-month, double-blind, placebo-controlled, parallel-group polysomnography study in adults aged 55 and older [1]. Lemborexant 5 mg and 10 mg both outperformed placebo on the co-primary endpoints of latency to persistent sleep and sleep efficiency at night 1 and month 1 [1]. At month 1, sleep efficiency for lemborexant 10 mg was 82.0% versus 74.6% for placebo (P<0.001) [1].

SUNRISE-2 (N=949) was a 12-month randomized trial including an active comparator arm of zolpidem extended-release 6.25 mg [11]. Lemborexant 5 mg and 10 mg showed statistically significant improvement in subjective sleep onset latency versus zolpidem ER at month 6, and sleep quality was maintained through month 12 without evidence of rebound insomnia upon discontinuation [11]. The Lancet Neurology published the primary SUNRISE-2 results in 2019, noting that discontinuation-emergent adverse events were no more frequent with lemborexant than placebo [11].

A 24-week open-label extension study (N=949) demonstrated that patients taking lemborexant 10 mg maintained improvements in subjective total sleep time through week 24 without dose escalation [12]. Next-morning residual sleepiness, measured by the Karolinska Sleepiness Scale, was significantly lower with lemborexant 5 mg than with zolpidem ER 6.25 mg at month 6 (P<0.05), a clinically meaningful finding for patients who drive or operate machinery in the morning [11].

Falls and complex sleep behaviors are the adverse events of greatest regulatory concern with orexin-based sleep agents. The FDA prescribing information for lemborexant includes a class warning about complex sleep behaviors, including sleep-walking and sleep-driving, that may occur even at recommended doses [5]. Providers in New Hampshire should screen for these behaviors at follow-up visits and document any occurrence in the medical record.

Who Can Prescribe Dayvigo in New Hampshire?

Any New Hampshire-licensed prescriber with DEA Schedule IV authorization can prescribe lemborexant.

This group includes MDs and DOs in any specialty, nurse practitioners (NPs) with full prescriptive authority under their New Hampshire collaborative practice status, and physician assistants (PAs) with Schedule IV DEA registration [4]. New Hampshire is a full-practice-authority state for NPs, meaning they may prescribe independently without a physician collaboration agreement after completing their supervised clinical hours [4]. PAs in New Hampshire must maintain a practice agreement with a supervising physician, but Schedule IV prescribing is within scope when the agreement covers it [4].

Sleep medicine specialists, psychiatrists, primary care providers, and internal medicine physicians all routinely prescribe lemborexant in New Hampshire. Telehealth providers licensed in New Hampshire, including HealthRX-affiliated clinicians, carry the same prescriptive authority as in-person providers for this drug class.

Switching to Dayvigo From Another Sleep Medication

Patients currently taking zolpidem, trazodone, or another sleep aid can transition to lemborexant under provider guidance.

No washout period is required before starting lemborexant. Providers generally taper the prior agent over 1 to 2 weeks while starting lemborexant at 5 mg to allow tolerance assessment before cross-taper completion [5]. Combining lemborexant with other CNS depressants during the overlap period may increase sedation, so the FDA label recommends starting at 5 mg and reassessing [5]. Patients discontinuing benzodiazepines should be tapered gradually regardless of what replaces them, given the withdrawal risk associated with GABA-A receptor dependence [13].

A 2020 analysis published in the Journal of Clinical Sleep Medicine examined orexin receptor antagonist discontinuation patterns and found that abrupt discontinuation of lemborexant did not produce the rebound insomnia seen with zolpidem in approximately 80% of patients who stopped the drug at the end of SUNRISE-2 [14]. This makes it a reasonable option for patients who need scheduled treatment rather than nightly maintenance therapy.

Dayvigo Dosing and Administration in New Hampshire Clinical Practice

The standard starting dose is 5 mg taken once per night, immediately before bed, with at least 7 hours remaining before the planned wake time.

The prescriber may increase to 10 mg if 5 mg is tolerated but insufficiently effective. Dose increases should occur no sooner than 7 days after starting the lower dose to allow adequate trial [5]. Taking lemborexant with or shortly after a high-fat meal delays the time to peak plasma concentration by approximately 2 hours, which may reduce its sleep-onset effect on nights when a large dinner is eaten late [5]. Patients should be counseled to take the medication on an empty or light-meal stomach for best onset.

CYP3A4 inhibitors such as fluconazole, clarithromycin, and grapefruit juice increase lemborexant plasma exposure and may require dose reduction to 5 mg [5]. CYP3A4 inducers such as rifampin can reduce efficacy and should prompt a discussion about alternative agents [5]. The full interaction table in the FDA prescribing information is the authoritative reference for New Hampshire providers managing polypharmacy patients [5].

Patients aged 65 and older should start at 5 mg given data from SUNRISE-1, which enrolled patients 55 and older and showed that next-morning impairment was more pronounced at 10 mg in this age group [1]. The AASM guideline on pharmacotherapy in older adults recommends using the lowest effective dose of any sedative-hypnotic, consistent with the lemborexant 5 mg starting strategy [2].

New Hampshire residents can begin the HealthRX intake process online. A provider licensed in New Hampshire will review the clinical history, conduct a video visit, and, if appropriate, transmit an electronic prescription to the pharmacy of the patient's choice that same day.